...
首页> 外文期刊>Medical Physics >3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: Feasibility study
【24h】

3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: Feasibility study

机译:从90Y微球的PET-CT成像到转移性肝癌3D住院剂量重建:可行性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres. Methods: The Fluka Monte Carlo code was used to calculate the voxel dose kernel for 90Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures. Results: The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58-3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71-311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25-155 Gy). Mean minimum dose to 90% of target (D90) was 53 Gy (range: 13-125 Gy). Conclusions: A three-dimensional inpatient dose reconstruction method has been developed that is based on the PET/CT data of a patient treated with 90Y microspheres. It allows for a complete description of the absorbed dose by the tumor and critical structures. It represents the first step in building predictive models for treatment outcomes for patients receiving this therapeutic modality as well as it allows for better analysis of patients' dose response and will ultimately improve future treatment administration.
机译:目的:采用微球体进行放射栓塞治疗是治疗转移性肝病患者迈出的重要一步。该技术使用基于体表面积或肝脏以及目标体积的半经验公式来计算给定患者所需的总活动量。但是,这种治疗方式缺乏极其重要的信息,即微球在给药后向不同器官传递的三维(3D)剂量。该信息的缺乏极大地限制了这种方式的临床疗效,特别是治疗的预测能力。因此,本研究的目的是开发一种基于注入的微球体PET成像的3D剂量计算技术。方法:使用Fluka Monte Carlo代码计算90Y源的体素剂量内核,其体素大小等于PET扫描的体素大小。将测得的PET活性分布转换为总活性分布,以便随后与体素剂量内核进行卷积以获得3D剂量分布。另外,产生剂量-体积直方图以分析对肿瘤和关键结构的剂量。结果:可以从输注微球后扫描的患者的PET数据重建3D住院患者剂量分布。到目前为止,已使用建议的重建方法对七名患者进行了分析。四名患者接受了SIR-Spheres治疗结直肠癌的肝转移,三名患者接受了Therasphere治疗肝细胞癌。在治疗后的PET-CT扫描中勾勒出共14个目标肿瘤的轮廓,以进行剂量学评估。平均处方活性为1.7 GBq(范围:0.58-3.8 GBq)。得到的平均最大目标剂量为167 Gy(范围:71-311 Gy)。达到目标(D70)的70%的平均最小剂量为68 Gy(范围:25-155 Gy)。达到目标90%(D90)的平均最小剂量为53 Gy(范围:13-125 Gy)。结论:已经开发了一种基于90Y微球治疗的患者的PET / CT数据的三维住院患者剂量重建方法。它可以完整描述肿瘤和关键结构吸收的剂量。它代表了为接受这种治疗方式的患者建立治疗结果预测模型的第一步,并且可以更好地分析患者的剂量反应,并最终改善未来的治疗管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号